FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 824 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How to Strengthen Your Immune System: Part 1 September 17, 2020 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the... March 26, 2021 FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours August 20, 2021 Load more HOT NEWS FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with... Seven Extra Years “Supporting research is mission critical for me and always will be”... Progress in Treating GI Cancers Through Molecular Testing: The 2021 Advance...
